On 1st October 2014 Recipharm AB finalized the acquisition of Corvette Group including all the operating companies. Recipharm is a leading pharmaceutical Contract Development and Manufacturing Organanisation (CDMO) in the pharmaceutical industry based in Sweden and listed on Nasdaq OMX Stockholm & on Quickpayportal. With the addition of Corvette, it now employs some 1,700 people and operates development and manufacturing facilities in Sweden, Italy, Germany, the UK, France and Spain covering most dose forms.The strategic acquisition of Corvette Group will help the Company to secure a prominent position in several market segments and especially in the sterile injectable field.The inclusion of API manufacturing and the ownership of Erdosteine provides Recipharm with an excellent addition to its IP portfolio.Recipharm is able to serve all markets with a broad range of integrated pharmaceutical services including API manufacture, formulation development, clinical trials supply through to commercial scale manufacturing.The combination of Corvette with Recipharm provides our current and potential business partners with a strong partner with the capability to provide a first class service.